Overview

A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is a comparison between MK0787B and standard therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Amikacin
Anti-Bacterial Agents
Cilastatin
Cilastatin, Imipenem Drug Combination
Imipenem
Piperacillin, Tazobactam Drug Combination
Vancomycin